Aprea Therapeutics, Inc. (NASDAQ:APRE – Get Free Report)’s share price was down 2.5% during mid-day trading on Monday . The stock traded as low as $2.34 and last traded at $2.34. Approximately 10,321 shares traded hands during mid-day trading, a decline of 45% from the average daily volume of 18,909 shares. The stock had previously closed at $2.40.
Wall Street Analyst Weigh In
Separately, HC Wainwright reiterated a “buy” rating and issued a $20.00 price objective on shares of Aprea Therapeutics in a report on Wednesday, January 15th.
Aprea Therapeutics Price Performance
Institutional Trading of Aprea Therapeutics
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets acquired a new stake in Aprea Therapeutics during the fourth quarter valued at approximately $43,000. LPL Financial LLC acquired a new stake in Aprea Therapeutics during the fourth quarter valued at approximately $53,000. Landscape Capital Management L.L.C. acquired a new stake in Aprea Therapeutics during the fourth quarter valued at approximately $116,000. Finally, Stonepine Capital Management LLC lifted its stake in Aprea Therapeutics by 8.8% during the fourth quarter. Stonepine Capital Management LLC now owns 149,221 shares of the company’s stock valued at $491,000 after purchasing an additional 12,047 shares during the last quarter. 34.19% of the stock is owned by institutional investors and hedge funds.
About Aprea Therapeutics
Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.
Further Reading
- Five stocks we like better than Aprea Therapeutics
- How to Invest in Biotech Stocks
- Can TikTok Stock Picks Really Make You Rich?
- The Role Economic Reports Play in a Successful Investment Strategy
- The “Quality” Rotation: Back to Basics Investing
- Top Biotech Stocks: Exploring Innovation Opportunities
- Occidental Petroleum: 4 Reasons to Love These Prices
Receive News & Ratings for Aprea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aprea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.